SCHEMBL31199145

SCHEMBL31199145

CC(C)n1nc(C(=O)N2CCN(c3ccc([N+](=O)[O-])cc3)CC2)c2ccccc2c1=O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.55
▸ GAA P10253 2/20 0.55
▸ LMNA P02545 2/20 0.55
▸ MAPT P10636 6/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ HTT P42858 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ STAT3 P40763 1/20 0.49
▸ STAT1 P42224 1/20 0.49
▸ PKM P14618 1/20 0.48
▸ POLB P06746 4/20 0.48
▸ THRB P10828 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ CRHBP P24387 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30976420 0.86 ALDH1A1 (0.56) ALDH1A1GAALMNAMAPTKMT2A
SCHEMBL31199155 0.84 ALDH1A1 (0.56) ALDH1A1GAALMNAMAPTKMT2A
SCHEMBL31199177 0.84 ALDH1A1 (0.59) ALDH1A1GAALMNAMAPTKMT2A
SCHEMBL31199213 0.84 ALDH1A1 (0.55) ALDH1A1GAALMNAMAPTKMT2A
SCHEMBL30976368 0.84 HTT (0.61) ALDH1A1GAALMNAMAPTKMT2A
SCHEMBL30976249 0.80 ALDH1A1 (0.56) ALDH1A1GAALMNAMAPTKMT2A
SCHEMBL30976302 0.79 LMNA (0.52) ALDH1A1GAALMNAMAPTKMT2A
SCHEMBL30976303 0.78 ALDH1A1 (0.56) ALDH1A1GAALMNAMAPTKMT2A
SCHEMBL30976314 0.78 ALDH1A1 (0.58) ALDH1A1GAALMNAMAPTKMT2A
SCHEMBL31199102 0.76 ALDH1A1 (0.55) ALDH1A1GAALMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027113-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS INC (US) 2026-01-29 — — US disclosed
US-12465603-B2 Phthalazinone based modulators for the treatment of disease SOLEY THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20240374589-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS, INC. 2024-11-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12465603-B2 Phthalazinone based modulators for the treatment of disease MKI67, BCL2, CCAR2 ALDH1A1 2021/4885GAA 432/4885LMNA 2935/4885
US-20260027113-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE NCOR1, NOP56, NCOR2 ALDH1A1 2922/4885GAA 3714/4885LMNA 2732/4885
US-20240374589-A1 PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE MKI67, HDAC6, BCL2 ALDH1A1 1827/4885GAA 350/4885LMNA 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback